{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-26-000034","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.051438+00:00","generated_at":"2026-05-15T00:34:21.435901+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bio-Rad Q1 GAAP net loss $527M ($19.55/share); net sales +1.1% to $592.1M","bullets":["Net sales $592.1M, up 1.1% YoY; GAAP gross margin 52.3% (flat YoY), non-GAAP gross margin 53.1%.","GAAP net loss $527.1M (diluted EPS -$19.55) vs prior-year net income $64.0M ($2.29).","Non-GAAP net income $50.9M ($1.89 diluted EPS); non-GAAP operating income $39.3M, down from $63.0M.","Operating cash flow $108.1M; free cash flow $78.1M; repurchased ~176k shares during Q1.","Management cited challenging academic markets and Middle East conflict as headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-26-000034","json":"https://secwatch.observer/filing/0000012208-26-000034.json","markdown":"https://secwatch.observer/filing/0000012208-26-000034.md","text":"https://secwatch.observer/filing/0000012208-26-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220826000034/0000012208-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220826000034/bio-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:34:21.435901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a957a7e6e7606e50106379574b542b3f9cb9fed4","claim":"BIO-RAD LABORATORIES, INC. reported first quarter ended March 31, 2026 results: revenue $592.1 million, net income $(527.1) million, EPS $(19.55) per diluted share.","evidence_excerpt":"Financial Results Highlights GAAP Results Q1 2026 Q1 2025 Net sales (millions) $ 592.1 $ 585.4 Gross margin 52.3 % 52.3 % Income from operations (millions) $ 34.1 $ 23.7 Net income (loss) (millions) $ (527.1) $ 64.0 Income (loss) per diluted share $ (19.55) $ 2.29","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220826000034/0000012208-26-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$592.1 million"},{"label":"Net income","value":"$(527.1) million"},{"label":"EPS","value":"$(19.55) per diluted share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}